Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Stem Cells (Dayton, Ohio)|June 11, 2017
Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug ScreeningAnne G Christensen, Sidse Ehmsen, Mikkel G Terp, et al.NPJ Precision Oncology|September 24, 2022
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancerAbeer J Al-Qasem, Carla L Alves, Sidse Ehmsen, et al.Cell Death & Disease|November 8, 2019
A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescenceNadine H Brückmann, Sofie N Bennedsen, Pascal H G Duijf, et al.Molecular Oncology|November 4, 2014
Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instabilityKatrine B V Greve, Jonas N Lindgreen, Mikkel G Terp, et al.Journal for Immunotherapy of Cancer|September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activityOdd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.NPJ Precision Oncology|March 9, 2026
Pulmonary surfactant protein D reduces lung cancer progression associated with decreased IL-4/STAT6 signalingAli Mohammadi, Mohammed Inayatullah, Anders Schlosser, et al.Science Translational Medicine|December 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancerCarla L Alves, Leena Karimi, Mikkel G Terp, et al.Cancer Research|September 10, 2025
SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast CancerRikkemaja Isahbell J Møldrup, Mikkel G Terp, Simon T Jakobsen, et al.JCI Insight|October 11, 2019
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancerLouise A Koopman, Mikkel G Terp, Gijs G Zom, et al.Pageof 4